New Zealand, science policy & COVID-19. Lessons for the next pandemic.

Since March 2020 it was known that risk for severe COVID-19 was stratified to the aged & infirm & to those with multiple (multimorbid) health conditions.

Since 2020 early treatments were designed to be taken at home to prevent viral replication; to boost the immune system & to reduce severe COVID-19 including inflammation & clotting. Access to early treatment in NZ without subsidy, will be out of reach for low income groups who are at higher risk of multimorbidity. Why has early treatment been ignored by the New Zealand government?

In July 2022 the NZ government & media still limit advice to vaccinate, mask, test & isolate. Mandates for healthcare workers continue, for an mRNA gene therapy that cannot prevent transmission of infection; & for which over 1000 studies in the peer reviewed literature demonstrate harm.

There is no evidence that the NZ government has been strategically & methodologically reviewing the peer reviewed literature over 2020-2022 to identify new knowledges relating to mRNA gene therapy safety & efficacy; to recognise risk by age & health status; & to survey treatments with a strong safety profile which prevent hospitalisation & death.

Science policy & resultant legislation, like democracy, must conform to principles of transparency & accountability.

Principles of administrative law infer & require that such work would be undertaken.

Will a single, novel mRNA genetic therapy be mandated in the 'next' pandemic?

[email protected]
TalkingRisk.NZ